Signia Therapeutics: Funding, Investors & Team (Sep 2026)
Signia Therapeutics proposes a breakthrough strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses. These antiviral candidates could be directly evaluated in phase II clinical trials and/or quickly available in response to any widespread outbreak for which the medical community and patients have limited options.
Signia Therapeutics has raised $3.4M across 2 funding rounds on record, the most recent a Grant of $1.9M announced in Jan 2022.
That round is below the $4.8M median round size for Health Care companies tracked on FundedIQ over the last two years.
Signia Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2022.
Signia Therapeutics Funding Rounds
Signia Therapeutics raised $1.5M in an undisclosed round announced in Oct 2021.
3 months later, a Grant of $1.9M was announced in Jan 2022.
Signia Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Signia Therapeutics Funding Compared to Other Health Care Startups
Signia Therapeutics' latest round of $1.9M is below the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Signia Therapeutics in Health Care and Villeurbanne
Companies Similar to Signia Therapeutics
Implicity is a developer of a Saas-based remote monitoring platform designed to provide smart monitoring of…
Beams is a producer of medical devices for cancerology based on the use of particles β.
Padoa is an occupational health software firm that develops a tool for monitoring the health of employees.…
CILcare specializes in providing drug solutions for hearing and ear disorders.
MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials,…
noa is a digital fitness and wellness company that offers premium, structured training programs for strength,…
Semeia offers patient monitoring solution designed to support medical followup of patients, remotely and in…
Signadori Bio is the next-generation cellular immunotherapy for cancer cure.This has culminated in the…
Axomove is an e-wellbeing application that spends significant time in video actual activities.
Parallel helps coding agent works side by side with hospital teams to deliver faster and more accurate…
May Health has created a new solution for infertility caused by Polycystic Ovary Syndrome (PCOS) that is…
MedinCell is an injectable slow-release drug specialist company.
Signia Therapeutics Funding FAQs
What does Signia Therapeutics do?
Signia Therapeutics proposes a breakthrough strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses. These antiviral candidates could be directly evaluated in phase II clinical trials and/or quickly available in response to any widespread outbreak for which the medical community and patients have limited options.
How much funding has Signia Therapeutics raised?
Signia Therapeutics has raised $3.4M across 2 rounds on record. The most recent is a Grant of $1.9M announced in Jan 2022.
When did Signia Therapeutics last raise funding?
Signia Therapeutics' most recent funding round on record is a Grant of $1.9M, announced in Jan 2022.
Who is the CEO of Signia Therapeutics?
Philippe Personne is listed as CEO at Signia Therapeutics.
Where is Signia Therapeutics headquartered?
Signia Therapeutics is based in Villeurbanne, Rhone-Alpes, France.
How many employees does Signia Therapeutics have?
Signia Therapeutics is in the 1-10 employee band.
How does Signia Therapeutics' funding compare to other Health Care startups?
Signia Therapeutics' latest round of $1.9M is below the $4.8M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Signia Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Signia Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.